Brainomix said its e-Lung software detects lung scarring and may help with earlier diagnosis and more accurate monitoring of ...
Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with ...
For the first time in more than 10 years, idiopathic pulmonary fibrosis (IPF) care teams and patients will have a new treatment option following the Oct. 7 approval of Jascayd (nerandomilast) by the U ...
Guest writer Kylene Henderson recalls the lengthy journey she and her husband faced to get answers and a pulmonary fibrosis diagnosis.
Columnist Sam Kirton shares his thoughts on recent CDC vaccine recommendations, as well as his experience before and after transplant.
The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung ...
My journey to a diagnosis of idiopathic pulmonary fibrosis (IPF) began in the fall of 2016, when I was 59. It all started with a persistent cough. While the cough was annoying, especially to my wife, ...
Treatment with the experimental therapy nerandomilast appears to reduce the risk of death in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), according to a ...
Pulmonary fibrosis (PF) is characterized by scarring, or fibrosis, in the lungs, leading to breathing difficulties, dry cough, muscle aches, and unintended weight loss. Because these symptoms also are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results